{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:52:13Z","timestamp":1789167133570,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03467-2","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:31:37Z","timestamp":1761046297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The oncogenic role of miR-155 on oral cancer progression and treatment strategies"],"prefix":"10.1007","volume":"16","author":[{"given":"Alexandra Iulia","family":"Aghiorghiesei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Mehterov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Nutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Vladimirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Nonchev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos K.","family":"Kontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rares","family":"Buduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Berindan-Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-016-0512-8","volume":"15","author":"M Manikandan","year":"2016","unstructured":"Manikandan M, Deva Magendhra Rao AK, Arunkumar G, et al. Oral squamous cell carcinoma: microrna expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer. 2016;15:28.","journal-title":"Mol Cancer"},{"key":"3467_CR2","doi-asserted-by":"publisher","first-page":"825266","DOI":"10.3389\/fphar.2022.825266","volume":"13","author":"P Kumari","year":"2022","unstructured":"Kumari P, Debta P, Dixit A. Oral potentially malignant disorders: etiology, pathogenesis, and transformation into oral cancer. Front Pharmacol. 2022;13:825266.","journal-title":"Front Pharmacol"},{"issue":"15","key":"3467_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153696","volume":"13","author":"L Lorini","year":"2021","unstructured":"Lorini L, Bescos Atin C, Thavaraj S, et al. Overview of oral potentially malignant disorders: from risk factors to specific therapies. Cancers (Basel). 2021;13(15): 13:15.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3467_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s13402-020-00521-9","volume":"43","author":"F Huang","year":"2020","unstructured":"Huang F, Xin C, Lei K, Bai H, Li J, Chen Q. Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma. Cell Oncol (Dordr). 2020;43(5):763\u201377.","journal-title":"Cell Oncol (Dordr)"},{"key":"3467_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104916","volume":"111","author":"W D\u2019Souza","year":"2020","unstructured":"D\u2019Souza W, Kumar A. Micrornas in oral cancer: moving from bench to bed as next generation medicine. Oral Oncol. 2020;111: 104916.","journal-title":"Oral Oncol"},{"issue":"5","key":"3467_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/jcb.24038","volume":"113","author":"RS Redis","year":"2012","unstructured":"Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Non-coding RNAs as theranostics in human cancers. J Cell Biochem. 2012;113(5):1451\u20139.","journal-title":"J Cell Biochem"},{"issue":"29","key":"3467_CR7","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2174\/0929867311320290002","volume":"20","author":"C Braicu","year":"2013","unstructured":"Braicu C, Calin GA, Berindan-Neagoe I. Micrornas and cancer therapy - from bystanders to major players. Curr Med Chem. 2013;20(29):3561\u201373.","journal-title":"Curr Med Chem"},{"issue":"10","key":"3467_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.oraloncology.2008.01.002","volume":"44","author":"CC Gomes","year":"2008","unstructured":"Gomes CC, Gomez RS. Microrna and oral cancer: future perspectives. Oral Oncol. 2008;44(10):910\u20134.","journal-title":"Oral Oncol"},{"key":"3467_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122620","author":"AI Irimie","year":"2017","unstructured":"Irimie AI, Braicu C, Sonea L, et al. A looking-glass of non-coding RNAs in oral cancer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18122620.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3467_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ. Micrornas: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522\u201331.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"3467_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15407\/exp-oncology.2024.02.139","volume":"46","author":"O Burtyn","year":"2024","unstructured":"Burtyn O, Borikun T, Rossylna O, Kopchak A. Kravets capital O C. Clinical significance of salivary Mir-21, -155, and \u2013\u2009375 in patients with squamous cell carcinoma of oral cavity. Exp Oncol. 2024;46(2):139\u201345.","journal-title":"Exp Oncol"},{"issue":"2","key":"3467_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/cells14020091","volume":"14","author":"M Jaksic Karisik","year":"2025","unstructured":"Jaksic Karisik M, Lazarevic M, Mitic D, et al. Microrna-21 as a regulator of cancer stem cell properties in oral cancer. Cells. 2025;14(2):91.","journal-title":"Cells"},{"issue":"4","key":"3467_CR13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-09-2291","volume":"70","author":"CJ Liu","year":"2010","unstructured":"Liu CJ, Tsai MM, Hung PS, et al. MiR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010;70(4):1635\u201344.","journal-title":"Cancer Res"},{"issue":"14","key":"3467_CR14","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.7150\/ijms.102123","volume":"21","author":"H Qian","year":"2024","unstructured":"Qian H, Maghsoudloo M, Kaboli PJ, et al. Decoding the promise and challenges of miRNA-Based cancer therapies: an essential update on miR-21, miR-34, and miR-155. Int J Med Sci. 2024;21(14):2781\u201398.","journal-title":"Int J Med Sci"},{"key":"3467_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585976","volume":"10","author":"L Wang","year":"2020","unstructured":"Wang L, Chen Y, Yan Y, et al. MiR-146a overexpression in oral squamous cell carcinoma potentiates cancer cell migration and invasion possibly via targeting HTT. Front Oncol. 2020;10: 585976.","journal-title":"Front Oncol"},{"issue":"2","key":"3467_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jds.2022.09.001","volume":"18","author":"Y-T Liu","year":"2023","unstructured":"Liu Y-T, Yu C-C, Lu M-Y, et al. MiR-146a participates in the regulation of cancer stemness of oral carcinoma cells. J Dent Sci. 2023;18(2):503\u20139.","journal-title":"J Dent Sci"},{"key":"3467_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.18632\/oncotarget.28717","volume":"16","author":"JP Jayaprakash","year":"2025","unstructured":"Jayaprakash JP, Karemore P, Khandelia P. METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p\/SMAD4 axis. Oncotarget. 2025;16:291\u2013309.","journal-title":"Oncotarget"},{"key":"3467_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00410-18","author":"S Zargar","year":"2019","unstructured":"Zargar S, Tomar V, Shyamsundar V, Vijayalakshmi R, Somasundaram K, Karunagaran D. A feedback loop between MicroRNA 155 (miR-155), programmed cell death 4, and activation protein 1 modulates the expression of miR-155 and tumorigenesis in tongue cancer. Mol Cell Biol. 2019. https:\/\/doi.org\/10.1128\/MCB.00410-18.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"3467_CR19","doi-asserted-by":"publisher","first-page":"220070","DOI":"10.1098\/rsob.220070","volume":"12","author":"O Dawson","year":"2022","unstructured":"Dawson O, Piccinini AM. MiR-155-3p: processing by-product or rising star in immunity and cancer? Open Biol. 2022;12(5):220070.","journal-title":"Open Biol"},{"key":"3467_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072245","author":"O Zanoaga","year":"2021","unstructured":"Zanoaga O, Braicu C, Chiroi P, et al. The role of miR-155 in nutrition: modulating cancer-associated inflammation. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13072245.","journal-title":"Nutrients"},{"issue":"10","key":"3467_CR21","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.21037\/tcr-24-543","volume":"13","author":"Z Guo","year":"2024","unstructured":"Guo Z, Tian J-J, Wang Y, et al. Mir-155-5p regulates autophagy and apoptosis of glioma cells through RICTOR. Transl Cancer Res. 2024;13(10):5509\u201321.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"3467_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jop.12351","volume":"45","author":"O Baba","year":"2016","unstructured":"Baba O, Hasegawa S, Nagai H, et al. Microrna-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis. J Oral Pathol Med. 2016;45(4):248\u201355.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"3467_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11033-024-09234-w","volume":"51","author":"R Maheswari","year":"2024","unstructured":"Maheswari R, Urs AB, Kumar P, Koner BC, Guru SA, Rawat G. Exploring miR-155-5p and miR-1246 as diagnostic and prognostic markers in oral squamous cell carcinoma. Mol Biol Rep. 2024;51(1):341.","journal-title":"Mol Biol Rep"},{"key":"3467_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biology11050651","author":"M Dioguardi","year":"2022","unstructured":"Dioguardi M, Spirito F, Sovereto D, et al. Biological prognostic value of miR-155 for survival outcome in head and neck squamous cell carcinomas: systematic review, meta-analysis and trial sequential analysis. Biology. 2022. https:\/\/doi.org\/10.3390\/biology11050651.","journal-title":"Biology"},{"issue":"2","key":"3467_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.oooo.2013.10.017","volume":"117","author":"YH Ni","year":"2014","unstructured":"Ni YH, Huang XF, Wang ZY, et al. Upregulation of a potential prognostic biomarker, miR-155, enhances cell proliferation in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(2):227\u201333.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"9","key":"3467_CR26","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.21873\/anticanres.12842","volume":"38","author":"H Kim","year":"2018","unstructured":"Kim H, Yang JM, Ahn SH, Jeong WJ, Chung JH, Paik JH. Potential oncogenic role and prognostic implication of MicroRNA-155-5p in oral squamous cell carcinoma. Anticancer Res. 2018;38(9):5193\u2013200.","journal-title":"Anticancer Res"},{"key":"3467_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706095","volume":"11","author":"B Liu","year":"2021","unstructured":"Liu B, Hu J, Zhao H, Zhao L, Pan S. Microrna-155-5p contributes to 5-fluorouracil resistance through down-regulating TP53INP1 in oral squamous cell carcinoma. Front Oncol. 2021;11: 706095.","journal-title":"Front Oncol"},{"key":"3467_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1072579","volume":"12","author":"N Mehterov","year":"2022","unstructured":"Mehterov N, Sacconi A, Pulito C, et al. A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. Front Oncol. 2022;12: 1072579.","journal-title":"Front Oncol"},{"issue":"5","key":"3467_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5125\/jkaoms.2020.46.5.341","volume":"46","author":"N Emami","year":"2020","unstructured":"Emami N, Mohamadnia A, Mirzaei M, Bayat M, Mohammadi F, Bahrami N. MiR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers. J Korean Assoc Oral Maxillofac Surg. 2020;46(5):341\u20137.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"3","key":"3467_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s11033-021-07033-1","volume":"49","author":"LE Kerche","year":"2022","unstructured":"Kerche LE, de Sousa EA, Squarize CH, et al. EMT in salivary gland tumors: the expression of MicroRNAs miR-155 and miR-200c is associated with clinical-pathological parameters. Mol Biol Rep. 2022;49(3):2157\u201367.","journal-title":"Mol Biol Rep"},{"key":"3467_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041031","author":"SG Doukas","year":"2020","unstructured":"Doukas SG, Vageli DP, Lazopoulos G, Spandidos DA, Sasaki CT, Tsatsakis A. The effect of NNK, a tobacco smoke carcinogen, on the MiRNA and mismatch DNA repair expression profiles in lung and head and neck squamous cancer cells. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9041031.","journal-title":"Cells"},{"issue":"10","key":"3467_CR32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/jop.12300","volume":"44","author":"M Manikandan","year":"2015","unstructured":"Manikandan M, Deva Magendhra Rao AK, Rajkumar KS, Rajaraman R, Munirajan AK. Altered levels of miR-21, miR-125b-2*, miR-138, miR-155, miR-184, and miR-205 in oral squamous cell carcinoma and association with clinicopathological characteristics. J Oral Pathol Med. 2015;44(10):792\u2013800.","journal-title":"J Oral Pathol Med"},{"key":"3467_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2018.04.021","volume":"82","author":"C Bersani","year":"2018","unstructured":"Bersani C, Mints M, Tertipis N, et al. Microrna-155, -185 and \u2013 193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma. Oral Oncol. 2018;82:8\u201316.","journal-title":"Oral Oncol"},{"key":"3467_CR34","doi-asserted-by":"publisher","DOI":"10.1590\/1678-7757-2024-0215","volume":"32","author":"R Zhou","year":"2024","unstructured":"Zhou R, Chen Z, Cai Y, et al. The simultaneous miR-155-5p overexpression and miR-223-3p inhibition can activate pEMT in oral squamous cell carcinoma. J Appl Oral Sci. 2024;32: e20240215.","journal-title":"J Appl Oral Sci"},{"key":"3467_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/978-1-62703-083-0_24","volume":"936","author":"JM Yoshizawa","year":"2013","unstructured":"Yoshizawa JM, Wong DT. Salivary MicroRNAs and oral cancer detection. Methods Mol Biol. 2013;936:313\u201324.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3467_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12903-023-03155-z","volume":"23","author":"M Mehdipour","year":"2023","unstructured":"Mehdipour M, Shahidi M, Anbari F, et al. Salivary level of microRNA-146a and microRNA-155 biomarkers in patients with oral lichen planus versus oral squamous cell carcinoma. BMC Oral Health. 2023;23(1):433.","journal-title":"BMC Oral Health"},{"issue":"5","key":"3467_CR37","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3892\/ijmm.2016.2529","volume":"37","author":"Q Zeng","year":"2016","unstructured":"Zeng Q, Tao X, Huang F, et al. Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6\/cyclin D2. Int J Mol Med. 2016;37(5):1274\u201380.","journal-title":"Int J Mol Med"},{"issue":"1","key":"3467_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1074\/jbc.M112.425736","volume":"288","author":"MI Rather","year":"2013","unstructured":"Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem. 2013;288(1):608\u201318.","journal-title":"J Biol Chem"},{"issue":"13","key":"3467_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.18632\/oncotarget.27531","volume":"11","author":"P Kirave","year":"2020","unstructured":"Kirave P, Gondaliya P, Kulkarni B, et al. Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition. Oncotarget. 2020;11(13):1157\u201371.","journal-title":"Oncotarget"},{"issue":"5","key":"3467_CR40","first-page":"937","volume":"21","author":"S Fu","year":"2017","unstructured":"Fu S, Chen HH, Cheng P, Zhang CB, Wu Y. MiR-155 regulates oral squamous cell carcinoma Tca8113 cell proliferation, cycle, and apoptosis via regulating p27Kip1. Eur Rev Med Pharmacol Sci. 2017;21(5):937\u201344.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"3467_CR41","first-page":"639","volume":"5","author":"LL Leung","year":"2024","unstructured":"Leung LL, Qu X, Chen B, Chan JY. Extracellular vesicles in liquid biopsies: there is hope for oral squamous cell carcinoma. Extracell Vesicles Circ Nucleic Acids. 2024;5(4):639\u201359.","journal-title":"Extracell Vesicles Circ Nucleic Acids"},{"key":"3467_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030449","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Hiyake N, Hamada T, et al. Circulating microrna panel as a potential novel biomarker for oral squamous cell carcinoma diagnosis. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030449.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3467_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/biomedicines11030965","volume":"11","author":"A Roi","year":"2023","unstructured":"Roi A, Boia S, Rusu L-C, Roi CI, Boia ER, Rivi\u0219 M. Circulating miRNA as a biomarker in oral cancer liquid biopsy. Biomedicines. 2023;11(3):965.","journal-title":"Biomedicines"},{"issue":"4","key":"3467_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/ncrna8040060","volume":"8","author":"G Gattuso","year":"2022","unstructured":"Gattuso G, Crimi S, Lavoro A, et al. Liquid biopsy and circulating biomarkers for the diagnosis of precancerous and cancerous oral lesions. Non-coding RNA. 2022;8(4):60.","journal-title":"Non-coding RNA"},{"issue":"5","key":"3467_CR45","volume":"9","author":"M Dioguardi","year":"2023","unstructured":"Dioguardi M, Spirito F, Iacovelli G, et al. The potential MicroRNA prognostic signature in hnsccs: a systematic review. Noncoding RNA. 2023;9(5): 54.","journal-title":"Noncoding RNA"},{"key":"3467_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/dj7020048","author":"M Hunsaker","year":"2019","unstructured":"Hunsaker M, Barba G, Kingsley K, Howard KM. Differential microRNA expression of miR-21 and miR-155 within oral cancer extracellular vesicles in response to melatonin. Dent J (Basel). 2019. https:\/\/doi.org\/10.3390\/dj7020048.","journal-title":"Dent J (Basel)"},{"key":"3467_CR47","first-page":"3465","volume":"9","author":"C Tomuleasa","year":"2014","unstructured":"Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I. Nanopharmacology in translational hematology and oncology. Int J Nanomed. 2014;9:3465\u201379.","journal-title":"Int J Nanomed"},{"key":"3467_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105402","volume":"120","author":"CM Chen","year":"2021","unstructured":"Chen CM, Chu TH, Chou CC, Chien CY, Wang JS, Huang CC. Exosome-derived microRNAs in oral squamous cell carcinomas impact disease prognosis. Oral Oncol. 2021;120: 105402.","journal-title":"Oral Oncol"},{"key":"3467_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082009","author":"R Drula","year":"2020","unstructured":"Drula R, Ott LF, Berindan-Neagoe I, Pantel K, Calin GA. Micrornas from liquid biopsy derived extracellular vesicles: recent advances in detection and characterization methods. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12082009.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3467_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10555-017-9724-7","volume":"37","author":"R Bayraktar","year":"2018","unstructured":"Bayraktar R, Van Roosbroeck K. MiR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev. 2018;37(1):33\u201344.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3467_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1051\/medsci\/20143003017","volume":"30","author":"S Baulande","year":"2014","unstructured":"Baulande S, Criqui A, Duthieuw M. [Circulating MiRNAs as a new class of biomedical markers]. Med Sci (Paris). 2014;30(3):289\u201396.","journal-title":"Med Sci (Paris)"},{"issue":"8","key":"3467_CR52","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1021\/acs.molpharmaceut.1c00213","volume":"18","author":"AA Sayyed","year":"2021","unstructured":"Sayyed AA, Gondaliya P, Mali M, et al. MiR-155 inhibitor-laden exosomes reverse resistance to cisplatin in a 3D tumor spheroid and xenograft model of oral cancer. Mol Pharm. 2021;18(8):3010\u201325.","journal-title":"Mol Pharm"},{"key":"3467_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042167","author":"C Belnap","year":"2024","unstructured":"Belnap C, Divis T, Kingsley K, Howard KM. Differential expression of microRNA MiR-145 and MiR-155 downstream targets in oral cancers exhibiting limited chemotherapy resistance. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042167.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"3467_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11010-013-1688-5","volume":"381","author":"C Braicu","year":"2013","unstructured":"Braicu C, Pileczki V, Irimie A, Berindan-Neagoe I. P53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem. 2013;381(1\u20132):61\u20138.","journal-title":"Mol Cell Biochem"},{"issue":"4S","key":"3467_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2024.101906","volume":"125","author":"N Shayan","year":"2024","unstructured":"Shayan N, Ghiyasimoghaddam N, Mirkatuli HA, Baghbani M, Ranjbarzadhagh Z, Mohtasham N. The biomarkers for maintenance cancer stem cell features can be applicable in precision medicine of head and neck squamous cell carcinoma. J Stomatol Oral Maxillofac Surg. 2024;125(4S): 101906.","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"3467_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032673","author":"S Pomella","year":"2023","unstructured":"Pomella S, Cassandri M, Melaiu O, et al. DNA damage response gene signature as potential treatment markers for oral squamous cell carcinoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032673.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3467_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12935-025-03654-9","volume":"25","author":"KY Lee","year":"2025","unstructured":"Lee KY, Oh SY, Lee HJ, et al. MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma. Cancer Cell Int. 2025;25(1):30.","journal-title":"Cancer Cell Int"},{"key":"3467_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021244","author":"KC Huni","year":"2023","unstructured":"Huni KC, Cheung J, Sullivan M, Robison WT, Howard KM, Kingsley K. Chemotherapeutic drug resistance associated with differential miRNA expression of miR-375 and miR-27 among oral cancer cell lines. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021244.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3467_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12885-017-3930-0","volume":"18","author":"SJ Yu","year":"2018","unstructured":"Yu SJ, Yang L, Hong Q, Kuang XY, Di GH, Shao ZM. Microrna-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 2018;18(1):74.","journal-title":"BMC Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03467-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:02:57Z","timestamp":1761091377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03467-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03467-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1941"}}